# L20.89 (ATOPIC DERMATITIS)

## <b  style="color:red">Class VII (Least Potent)</b>
### <u  style="color:teal">Hydrocortisone</u>
- Formulations:
  - 0.5% Cream, Ointment, Lotion (OTC)
  - 1% Cream, Ointment, Lotion (OTC or Rx)
  - 2.5% Cream, Ointment, Lotion (Rx)
- Notes: OTC availability at ≤1%.

## <b  style="color:red">Class VI (Low Potency)</b>
### <u  style="color:teal">Desonide 0.05%</u>
- Formulations: Cream, Ointment, Lotion, Gel, Foam
- Brand Examples: DesOwen (cream), Tridesilon (ointment), Verdeso (foam), generics

### <u  style="color:teal">Fluocinolone Acetonide 0.01%</u>
- Formulations: Cream, Solution (scalp)
- Brand Examples: Capex (shampoo combo), Derma-Smoothe/FS (oil)
- Use: Mild AD, often for scalp or sensitive areas.
- Notes: Solution/oil forms used for scalp AD
!!! Note "To be approved"
  Alclometasone Dipropionate 0.05%, Fluocinolone Acetonide 0.025%

### <u  style="color:teal">Alclometasone Dipropionate 0.05%</u>
- Formulations: Cream, Ointment
- Brand Example: Aclovate, generics
- Notes: Approved for ages ≥1 year.

## <b  style="color:red">Class V (Lower-Mid Potency)</b>
### <u  style="color:teal">Hydrocortisone Butyrate 0.1%</u>
- Formulations: Cream, Ointment, Lotion, Solution
- Brand Examples: Locoid (cream/lotion), Locoid Lipocream

### <u  style="color:teal">Hydrocortisone Valerate 0.2%</u>
- Formulations: Cream, Ointment
- Brand Example: Westcort

### <u  style="color:teal">Hydrocortisone Probuate 0.1%</u>
- Formulations: Cream
- Brand Example: Pandel
- Notes: Less commonly used but FDA-approved for AD.

## <b  style="color:red">Class IV (Mid Potency)</b>
### <u  style="color:teal">Triamcinolone Acetonide</u>
- Formulations:
  - 0.025% Cream, Ointment
  - 0.1% Cream, Ointment, Lotion
  - 0.5% Cream, Ointment
- Brand Examples: Trianex, Kenalog, Aristocort
- Notes: 0.1% most common

### <u  style="color:teal">Fluocinolone Acetonide 0.025%</u>
- Formulations: Cream, Ointment
- Brand Example: Synalar
- Notes: Step up from 0.01%; short-term flare control.

### <u  style="color:teal">Desoximetasone 0.05%</u>
- Formulations: Cream, Gel
- Brand Example: Topicort
- Use: Moderate AD.

## <b  style="color:red">Class III (Upper-Mid Potency)</b>
### <u  style="color:teal">Fluticasone Propionate</u>
- Formulations:
  - 0.05% Cream
  - 0.005% Ointment
- Brand Example: Cutivate

### <u  style="color:teal">Betamethasone Valerate 0.1%</u>
- Formulations: Cream, Ointment, Lotion
- Brand Example: Valisone, Luxiq (foam)

### <u  style="color:teal">Desoximetasone 0.25%</u>
- Formulations: Cream, Ointment, Gel
- Brand Example: Topicort

## <b  style="color:red">Class II (High Potency)</b>
### <u  style="color:teal">Mometasone Furoate 0.1%</u>
- Formulations: Cream, Ointment, Lotion
- Brand Example: Elocon

### <u  style="color:teal">Fluocinonide 0.05%</u>
- Formulations: Cream, Ointment, Gel, Solution
- Brand Example: Lidex

### <u  style="color:teal">Halcinonide 0.1%</u>
- Formulations: Cream, Ointment
- Brand Example: Halog

### <u  style="color:teal">Amcinonide 0.1%</u>
- Formulations: Cream, Ointment, Lotion
- Brand Example: Cyclocort

## <b  style="color:red">Class I (Most Potent)</b>
### <u  style="color:teal">Clobetasol Propionate 0.05%</u>
- Formulations: Cream, Ointment, Lotion, Gel, Foam, Solution
- Brand Examples: Temovate, Clobex (lotion/foam), Olux (foam), generics

### <u  style="color:teal">Betamethasone Dipropionate 0.05% (Augmented)</u>
- Formulations: Cream, Ointment, Lotion, Gel
- Brand Example: Diprolene

### <u  style="color:teal">Diflorasone Diacetate 0.05%</u>
- Formulations: Cream, Ointment
- Brand Example: Psorcon

### <u  style="color:teal">Halobetasol Propionate 0.05%</u>
- Formulations: Cream, Ointment
- Brand Example: Ultravate

## <b  style="color:red">Calcineurin Inhibitors</b>
### <u  style="color:teal">Tacrolimus</u>
- Notes: FDA-approved for atopic dermatitis but used off-label for psoriasis.
### <u  style="color:teal">Pimecrolimus</u>
- Notes: Similarly approved for atopic dermatitis, used off-label.
### <u style="color:teal">Eucrisa</u>
- Notes: FDA-approved for atopic dermatitis

## <b style="color:red">Biologics</b>
!!! tip "Important"
    With biologics, it is <u>necessary</u> to invlude thoose lines (even if some portions was answered during Q&A)

    ```
    Patient will continue using topical emollients in problem areas. 
    Patient will not be on any biologics, jak inhibiters, or immunossupressants. 
    Patient is not immunocompromised.
    Patient has over 65% BSA.
    ```
### <u  style="color:teal">DUPIXENT</u>
- Approval: FDA-approved for adults with moderate-to-severe AD and infants (6 months+) in 2022.
!!! note
    For continuation of Dupixent to be approved
    ```
    Patient showed significant improvements (BSA less than 3%) and stabilization.
    ```
### <u  style="color:teal">ADBRY</u>
- Approval: FDA-approved in December 2021 for adults with moderate-to-severe AD.
### <u  style="color:teal">EBGLYSS</u>
- Approval: FDA-approved in October 2024 for adults and adolescents (12+, weighing at least 40 kg) with moderate-to-severe AD not adequately controlled with topical therapies.

## <b  style="color:red">Immunosuppressants</b>
- Prednisone, Cyclosporine, Methotrexate, Azathioprine, Mycophenolate Mofetil
- Notes: Commonly used off-label for moderate-to-severe AD refractory to other treatments.

## <b  style="color:red">JAK Inhibitors</b>

### <u  style="color:teal">Oral JAK Inhibitors</u>
#### <u  style="color:teal">CIBINQO</u>
- Approval: FDA-approved in January 2022 for adults with refractory moderate-to-severe AD not adequately controlled with other systemic drugs.
- Notes: Dosed at 100 mg or 200 mg daily.
#### <u  style="color:teal">RINVOQ</u>
- Approval: FDA-approved in January 2022 for adults and adolescents (12+) with moderate-to-severe AD not adequately controlled with other systemic drugs.
- Notes: Dosed at 15 mg or 30 mg daily.

### <u  style="color:teal">Topical JAK Inhibitors</u>
#### <u  style="color:teal">OPZELURA</u>
!!! note
    For opzelura to be approved, BSA has to be less than 20%
- Approval: FDA-approved in September 2021 for short-term, non-continuous treatment of mild-to-moderate AD in patients 12+.
- Notes: First topical JAK inhibitor for AD; applied as a cream, also approved for vitiligo (2022).
